Value of Heart Rate Lowering Therapy in Acute Myocarditis

NCT ID: NCT06312891

Last Updated: 2024-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2025-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the value of heart rate lowering therapy "pharmacological rest" on the short term in cases of myocarditis without LV dysfunction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocarditis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional anti-inflammatory treatment (control group).

No interventions assigned to this group

Conventional ttt PLUS Carvedilol.

No interventions assigned to this group

Conventional ttt PLUS Ivabradine.

Ivabradine

Intervention Type DRUG

heart rate lowering therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivabradine

heart rate lowering therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults: ≥18 years of age.
* Presentation: at least one of the following:

* Myopericarditis/ACS-like
* MINOCA
* Arrhythmias: brady or tachyarrhythmias.
* Unexplained compensated acute cardiomyopathy (excluded ischemic, valvular, hypertensive, metabolic, and toxic causes of cardiomyopathy as indicated clinically).
* TTE: LVEF\>40%
* CMR-confirmed myo(peri)carditis (Lake Louise criteria)

Exclusion Criteria

* • Rheumatic carditis.

* Connective tissue diseases (-ve ANA).
* Cancer chemotherapy.
* Toxicity from immunotherapy.
* Vaccine-related myocarditis.
* Presence of coronary artery disease.
* Peripartum (occurring during the last month of pregnancy or within 5 months after delivery)
* ECG: atrial fibrillation/flutter.
* Resuscitated sudden death.
* Early/initial phase of decompensated heart failure.
* Tamponade complicating pericarditis unless successfully managed.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sara Mahmoud Moustafa

Resident at student hospital , assiut university

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Hospital

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

sara mahmoud

Role: CONTACT

01016862195

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

sara mahmoud, master

Role: primary

01016862195

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VOHRLTIAM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Heart Rate Reduction in Heart Failure
NCT01178528 COMPLETED PHASE3